Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627816 | 0.84 | ALDH1A1 (0.52) | ALDH1A1CYP3A4KDM4EUSP2MAPT | |
| SCHEMBL5073657 | 0.83 | NR4A1 (0.54) | ALDH1A1CYP3A4KDM4EUSP2MAPT | |
| SCHEMBL11481973 | 0.82 | NR4A1 (0.52) | ALDH1A1CYP3A4MAPTMEN1KMT2A | |
| SCHEMBL7287393 | 0.81 | MAOB (0.51) | ALDH1A1CYP3A4KDM4EUSP2MAPT | |
| SCHEMBL108848 | 0.81 | PGR (0.59) | ALDH1A1CYP3A4KDM4EMAPTKMT2A | |
| SCHEMBL5361453 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4EUSP2MAPTMEN1 | |
| SCHEMBL9560109 | 0.81 | MAOB (0.57) | ALDH1A1KDM4EUSP2MEN1KMT2A | |
| SCHEMBL16007284 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP3A4KDM4EMAPTMEN1 | |
| SCHEMBL2656322 | 0.79 | CYP1A2 (0.43) | ALDH1A1CYP3A4KDM4EUSP2KMT2A | |
| SCHEMBL11796509 | 0.79 | MEN1 (0.54) | ALDH1A1CYP3A4KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118440013-A | Preparation method of quinazoline diketone compound | 安顺学院 | 2024-08-06 | — | — | CN | claimed |
| CN-108640919-B | Matrine derivative and sophoridine derivative containing aryl amidine or aminoquinoline structure and preparation method thereof | 广西大学 | 2020-09-08 | — | — | CN | claimed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-3796905-B1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | UNIV ILLINOIS (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-07-10 | — | — | US | disclosed |
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250129086-A1 | COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2025-04-24 | — | — | US | disclosed |
| CN-119768407-A | Protein phosphatase agonist and application thereof | 南京中瑞药业有限公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025062157-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| EP-4434978-A1 | COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF | TYK Medicines Inc. (CN) | 2024-09-25 | — | — | EP | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-6172078-B1 | PREVENTING WORSENING OF CEREBRAL STROKE; ANTIISCHEMIC AGENTS; BRAIN DISORDERS | TORAY INDUSTRIES, INC. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0911334-A1 | QUINOLINOMORPHINANE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1999-04-28 | — | — | EP | disclosed |
| US-4713383-A | ADENOSINE AND BENZODIAZEPINE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1987-12-15 | — | — | US | disclosed |
| US-4647565-A | 2-(2-quinazolinylaminoalkoxymethyl)-1,4-dihydropyridine derivatives as cardiovascular agents | PFIZER INC. (US) | 1987-03-03 | — | — | US | disclosed |
| EP-0168151-A1 | Dihydropyridine cardiovascular agents | Pfizer Limited (GB) | 1986-01-15 | — | — | EP | disclosed |
| US-3987192-A | ANTIALLERGENS AND ANTIANAPHYLAXID; 2'-CYANO-OXANILIC ACID | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | ESR2, ESRRG, GPER1 | ALDH1A1 1027/4885CYP3A4 1246/4885KDM4E 1046/4885 |
| US-20250129086-A1 | COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 2252/4885CYP3A4 1269/4885KDM4E 893/4885 |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | ALDH1A1 1335/4885CYP3A4 1181/4885KDM4E 2757/4885 |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | ESR2, ESRRG, GPER1 | ALDH1A1 1027/4885CYP3A4 1246/4885KDM4E 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.